McKesson (MCK) Q3 2026 earnings review
Oncology Booms, Medical-Surgical Falters
McKesson delivered a robust Q3 with 11% revenue growth and a 16% jump in Adjusted EPS, prompting a guidance raise. The story is a tale of two segments: Oncology & Multispecialty is exploding (+57% profit growth) driven by acquisitions and provider demand, while the Medical-Surgical business—slated for spin-off—is dragging (-10% profit) due to a weak illness season. Management raised full-year EPS guidance to $38.80–$39.20, signalling confidence that the oncology engine has enough torque to offset weakness elsewhere.
🐂 Bull Case
This segment is rapidly becoming the company's growth engine. Revenue jumped 37% and Adjusted Operating Profit surged 57% to $366M, driven by acquisitions (PRISM, Core Ventures) and organic volume. Margins expanded 36bps to 2.81%.
Prescription Technology Solutions (RxTS) continues to demonstrate operating leverage. While revenue grew 9%, Adjusted Operating Profit grew 18%, pushing margins to an impressive 18.5%.
🐻 Bear Case
The segment slated for separation is underperforming. Revenue was flat (+1%), but Adjusted Operating Profit fell 10% due to lower volumes in physician offices and a weak illness season. Margins compressed by over 110 basis points.
While the core pharma segment grew revenue by 9% to $88.3B, operating profit only grew 6%, implying margin compression (approx. 92bps vs 101bps prior year). Growth is volume-driven but slightly less profitable.
⚖️ Verdict: 🟢
Bullish. McKesson is effectively executing its pivot toward higher-margin oncology and technology services. The weakness in Medical-Surgical is a concern, but the upcoming separation of that business makes the core 'New McKesson' narrative even stronger.
Key Themes
Oncology & Multispecialty Breakout
Accelerating. The strategic shift to specialty care is paying off massively. This segment is no longer just a pilot; it's a primary profit driver. Revenue growth of 37% and profit growth of 57% validate the acquisitions of PRISM Vision and Florida Cancer Specialists. This segment is successfully offsetting slower growth in legacy distribution.
Medical-Surgical Drag
Decelerating. The Medical-Surgical segment posted a 10% profit decline on flat revenue (+1%). Management cites 'lower incidence of illness' and lower office visits. This is the third consecutive quarter of commentary regarding softness in this segment (Q1 +2% Rev, Q2 Flat Rev, Q3 +1% Rev). As McKesson prepares to spin this unit off, deteriorating fundamentals could impact the valuation or capital structure of the separation.
Europe Exit Finalized
McKesson closed the sale of its Norwegian retail and distribution businesses on Jan 30, 2026. This marks the completion of its multi-year strategy to exit Europe. This removes currency drag and operational complexity, allowing 100% focus on North American growth pillars.
Prescription Tech (RxTS) Leverage
Stable/Accelerating. RxTS continues to be a margin machine. Segment profit ($277M) grew twice as fast as revenue, driven by 'higher demand for access solutions' (likely GLP-1 prior authorizations). Margins expanded ~133bps YoY to 18.5%. This high-margin revenue stream is critical for blending up the consolidated margin profile.
Other KPIs
Stable. Up 9% YoY. Driven by increased prescription volumes and specialty products. While the growth is solid, it lags the blistering pace of FY25 (which saw ~15-19% growth), indicating normalization as they lap the onboarding of major strategic customers.
Reversing. FCF improved significantly. In the first nine months of FY25, FCF was negative $2.2B (due to timing/investments). YTD FY26 is positive $2.2B. This swing of +$4.4B supports the aggressive capital return strategy ($2.1B in buybacks YTD).
Accelerating. Adjusted OpEx increased 7% YoY, while Adjusted Gross Profit increased 10%. This positive jaw (Gross Profit growing faster than Expenses) demonstrates the operating leverage management has promised.
Guidance
Accelerating. Raised and narrowed from prior range of $38.35 - $38.85. The midpoint ($39.00) implies ~18% YoY growth. This is a strong signal that Q4 is expected to remain healthy despite Med-Surg headwinds.
Key Questions
Med-Surg Structural Weakness?
Medical-Surgical profit fell 10% this quarter following a flat Q2. Is this solely due to 'illness season' volatility, or are we seeing structural share loss or margin compression ahead of the planned spin-off?
North American Pharma Margin Compression
Revenue grew 9% while adjusted operating profit only grew 6%. What specific mix shifts or cost pressures are compressing margins in the core distribution business?
Rite Aid Credit Sustainability
GAAP results benefited from a credit related to the Rite Aid bankruptcy. Was this a one-time reversal of bad debt reserves, and is there any remaining exposure?